Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.

CONCLUSION: AC, including gemcitabine/docetaxel regimen, or AR did not reduce the recurrence rate in patients with early-stage uLMS.
PMID: 31307664 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - July 11, 2019 Category: Cancer & Oncology Authors: Chae SH, Shim SH, Chang M, Choi AY, Kang GG, Lee SJ, Kim SN Tags: Gynecol Oncol Source Type: research